Evidence map›Paper›PMID 34358215›Full record

ArticleVaccines2021

Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals.

Csaba Fehér, Roque Pastor-Lbáñez, Lorna Leal, Montserrat Plana, Mireia Arnedo, Henk-Jan van den Ham, Arno C Andeweg, Rob A Gruters, Francisco Díez-Fuertes, José Alcamí and 2 more

Abstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Csaba FehérInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute for Science and Technology, 08028 Barcelona, Spain.ORCID 0000-0001-6679-493X
Roque Pastor-LbáñezRetrovirology and Viral Immunopathology Laboratory, AIDS Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-0787-4638
Lorna LealInfectious Diseases Department, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-7887-6027
Montserrat PlanaRetrovirology and Viral Immunopathology Laboratory, AIDS Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Mireia ArnedoRetrovirology and Viral Immunopathology Laboratory, AIDS Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-6248-7780
Henk-Jan van den HamDepartment of Viroscience, Erasmus MC, 3000CA Rotterdam, The Netherlands.
Arno C AndewegDepartment of Viroscience, Erasmus MC, 3000CA Rotterdam, The Netherlands.
Rob A GrutersDepartment of Viroscience, Erasmus MC, 3000CA Rotterdam, The Netherlands.ORCID 0000-0002-8486-5903
Francisco Díez-FuertesInfectious Diseases Department, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.
José AlcamíInfectious Diseases Department, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-0023-7377
Patrick AloyInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute for Science and Technology, 08028 Barcelona, Spain.
Felipe GarcíaInfectious Diseases Department, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-7658-5832

Funding

amfAR, The Foundation for AIDS Research 108821-55-RGRLCERCA Program / Generalitat de Catalunya SGR 615European CommissionH2020- SC1-2016-RTD 731626Fondo de Investigación Sanitaria (FIS) AC16/00051Fondo de Investigación Sanitaria (FIS) PI15/00480Fondo de Investigación Sanitaria (FIS) PI18/ 00699Ministerio de Economía y Competitividad RTI2018-096309-B-I00Ministerio de Economía y Competitividad SAF2015-66193-RSpanish AIDS Research Network RD16/0025/0002
6 · The paper itself

Abstract

Systems vaccinology has seldomly been used in therapeutic HIV-1 vaccine research. Our aim was to identify early gene 'signatures' that predicted virus load control after analytical therapy interruption (ATI) in participants of a dendritic cell-based HIV-1 vaccine trial (DCV2). mRNA and miRNA were extracted from frozen post-vaccination PBMC samples; gene expression was determined by microarray method. In gene set enrichment analysis, responders showed an up-regulation of 14 gene sets (TNF-alpha/NFkB pathway, inflammatory response, the complement system, Il6 and Il2 JAK-STAT signaling, among others) and a down-regulation of 7 gene sets (such as E2F targets or interferon alpha response). The expression of genes regulated by three (miR-223-3p, miR-1183 and miR-8063) of the 9 differentially expressed miRNAs was significantly down-regulated in responders. The deregulation of certain gene sets related to inflammatory processes seems fundamental for viral control, and certain miRNAs may be important in fine-tuning these processes.

Indexed as

dendritic cell-based therapeutic HIV-1 vaccinedifferential gene expressiongene set enrichment analysismiRNAmRNA

Identifiers

PMID34358215
PMCPMC8310264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.